Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trab...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Incalci, M, Badri, N, Galmarini, C M, Allavena, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134488/
https://www.ncbi.nlm.nih.gov/pubmed/24755886
http://dx.doi.org/10.1038/bjc.2014.149
_version_ 1782330877218390016
author D'Incalci, M
Badri, N
Galmarini, C M
Allavena, P
author_facet D'Incalci, M
Badri, N
Galmarini, C M
Allavena, P
author_sort D'Incalci, M
collection PubMed
description Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment.
format Online
Article
Text
id pubmed-4134488
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-41344882014-08-26 Trabectedin, a drug acting on both cancer cells and the tumour microenvironment D'Incalci, M Badri, N Galmarini, C M Allavena, P Br J Cancer Minireview Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment. Nature Publishing Group 2014-08-12 2014-04-22 /pmc/articles/PMC4134488/ /pubmed/24755886 http://dx.doi.org/10.1038/bjc.2014.149 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Minireview
D'Incalci, M
Badri, N
Galmarini, C M
Allavena, P
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
title Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
title_full Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
title_fullStr Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
title_full_unstemmed Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
title_short Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
title_sort trabectedin, a drug acting on both cancer cells and the tumour microenvironment
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134488/
https://www.ncbi.nlm.nih.gov/pubmed/24755886
http://dx.doi.org/10.1038/bjc.2014.149
work_keys_str_mv AT dincalcim trabectedinadrugactingonbothcancercellsandthetumourmicroenvironment
AT badrin trabectedinadrugactingonbothcancercellsandthetumourmicroenvironment
AT galmarinicm trabectedinadrugactingonbothcancercellsandthetumourmicroenvironment
AT allavenap trabectedinadrugactingonbothcancercellsandthetumourmicroenvironment

Ejemplares similares